June 03, 2026 | Read online

Morning Radar: See Why (NASDAQ: FEED) Just Hit Our Screen With a Bang

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

Daily Edge Report Initiates Coverage On ENvue Medical, Inc. (NASDAQ: FEED) This Morning—Wednesday, June 3, 2026

Don’t miss the next breakout — get real-time alerts sent straight to your phone!

(NASDAQ: FEED) Tops Wednesday's MedTech Watchlist With 7 Explosive Potential Catalysts

June 3, 2026

Morning Radar: See Why (NASDAQ: FEED) Just Hit Our Screen With a BANG

Dear Reader,

What happens when a medical technology company moves beyond development and starts securing long-term adoption inside real hospital systems?

That's the question we found ourselves asking as a series of recent developments pushed ENvue Medical, Inc. (NASDAQ: FEED) onto our radar.

The company is targeting a large and often overlooked challenge in healthcare. More than 13M feeding tube placements are performed annually in the United States, yet approximately 85% are still completed without real-time visual guidance, often requiring radiology confirmation before nutritional support can begin.

ENvue's FDA-cleared ENvue® Navigation Platform was designed to address that issue by providing real-time bedside guidance during feeding tube placement procedures.

Over the past several weeks, the commercial story appears to have gained momentum.

Most notably, the company recently announced a three-year contract renewal with a 12-hospital integrated nonprofit health network that has standardized the ENvue™ Navigation Platform as its protocol for bedside feeding tube placement through 2028.

Shortly before that announcement, management renewed a three-year Group Purchasing Organization agreement providing access to more than 90 hospitals across 17 states, while also reporting a new USPTO Notice of Allowance tied to its broader technology portfolio.

Those developments are among the reasons (FEED) has moved to the top of our watchlist for Wednesday, June 3, 2026.

Another factor worth noting is the company's share structure. (FEED) currently has fewer than 6M shares listed as available to the public, creating a relatively limited float profile.

The stock also remains largely underfollowed, trending below $1 according to recent Barchart data.

Meanwhile, shares recently advanced approximately 26% in two sessions, moving from roughly $0.84 on May 20 to $1.06 on May 22.

With expanding hospital adoption, active commercial deployments, recurring revenue initiatives, and a growing intellectual property portfolio, we decided it was time to take a closer look at what may be developing behind the scenes.

Here's what you should know before the opening bell.

Inside The Medical Technology Platform Driving Growth At (FEED)

ENvue Medical, Inc. (Nasdaq: FEED) is a medical technology company focused on improving the safety and accuracy of enteral feeding tube placement through its proprietary ENvue® Navigation System. According to the company, the platform utilizes electromagnetic guidance technology that enables clinicians to visualize feeding tube placement in real time at the bedside, helping reduce reliance on traditional blind-placement methods.

The company's flagship ENvue® Navigation System combines body mapping technology, integrated sensors, and real-time navigation capabilities designed to assist healthcare providers during feeding tube placement procedures. Management has positioned the platform as a solution aimed at improving workflow efficiency while supporting patient safety across hospital settings.

Beyond its navigation platform, (FEED) also maintains a portfolio of acoustic wave technologies, including PainShield® and UroShield®. These products utilize proprietary Surface Acoustic Wave (SAW) technology designed for applications involving pain management, bacterial reduction, and biofilm disruption.

As commercialization efforts continue, (FEED) has reported expanding adoption of its navigation platform across healthcare systems and recently secured a three-year contract renewal with a 12-hospital health system. Management continues to focus on increasing utilization of the ENvue platform while advancing additional intellectual property and future product development initiatives.

Why The Enteral Feeding Device Market May Matter For (FEED)

ENvue Medical (Nasdaq: FEED) operates within the enteral feeding device market, a sector benefiting from long-term trends including an aging population, rising rates of chronic disease, and growing demand for clinical nutrition support. According to Grand View Research, the global enteral feeding devices market was valued at approximately $4.62B in 2025 and is projected to reach roughly $7.19B by 2033.

A major focus within the industry is improving the safety and efficiency of feeding tube placement procedures. Hospitals continue evaluating technologies that can provide enhanced placement guidance, workflow improvements, and reduced complication risks compared to traditional blind-placement methods.

As healthcare systems increasingly adopt technologies designed to improve procedural accuracy and patient outcomes, companies operating within enteral feeding navigation and nutritional support markets may continue benefiting from these broader industry trends.

Recent Milestones Driving Attention Toward (FEED)

• Hospital System Renewal: ENvue recently secured a three-year contract renewal with a 12-hospital nonprofit health system, extending use of the ENvue™ Navigation Platform through 2028.

• Expanded Healthcare Access: The company renewed a three-year Group Purchasing Organization agreement providing potential access to more than 90 hospitals across 17 states.

• Growing Commercial Footprint: Management recently reported deployment of the ENvue Navigation Platform across 39 U.S. hospitals as commercialization efforts continue to expand.

• Patent Progress: ENvue announced receipt of a USPTO Notice of Allowance covering its ultrasound-enhanced cannabinoid delivery technology, adding to the company's broader intellectual property portfolio.

• Recurring Revenue Growth: The company highlighted continued growth in consumable product sales associated with increasing ENvue system utilization.

• Pipeline Expansion Efforts: Management continues evaluating additional regulatory items, including potential pediatric applications and PICC-related uses for its navigation technology.

• Product Portfolio Development: ENvue also reported ongoing expansion of its ENFit syringe offerings and other enteral-care related products designed to support its commercial platform.

7 Factors Putting (FEED) At The Top Of Our Radar This Morning — Wednesday, June 3, 2026

Extremely Tight Share Structure: With fewer than 6M shares currently listed as available to the public.
Recent Commercial Expansion: The company recently secured a three-year contract renewal with a 12-hospital nonprofit health system, extending use of its ENvue™ Navigation Platform through 2028.
Broad Hospital Access: Management also renewed a three-year Group Purchasing Organization agreement that provides access to more than 90 hospitals across 17 states, potentially expanding future commercial access.
Growing Hospital Adoption: The ENvue® Navigation Platform has now been deployed across approximately 40 U.S. hospitals as the company continues expanding its commercial footprint.
FDA-Cleared Medical Technology: The company's ENvue® Navigation System is already FDA 510(k)-cleared and designed to provide real-time guidance for enteral feeding tube placement procedures.
Recent Intellectual Property Progress: ENvue recently announced a new USPTO Notice of Allowance tied to its technology portfolio, further expanding the company's intellectual property position.
Multiple Growth Initiatives Underway: Beyond its core navigation platform, management continues advancing additional items involving pediatric applications, PICC-related procedures, consumable product expansion, and acoustic wave technologies across its broader product portfolio.

Get (FEED) On Your Screen While It’s Still Early…

As we head into today's session, (FEED) appears to be entering a period where several notable developments are beginning to converge.

Recent contract renewals have expanded the company's reach across hospital networks spanning more than 90 facilities in 17 states, while adoption of its FDA-cleared ENvue® Navigation Platform continues to grow across U.S. healthcare systems. At the same time, management has highlighted ongoing intellectual property expansion, additional regulatory items, and continued growth in recurring consumable revenue.

When viewed together, the combination of commercial traction, expanding hospital access, recent patent progress, and an exceptionally tight share structure places (FEED) firmly on our radar heading into tomorrow's session.

Get (FEED) on your screen while it’s still early.

Also, keep an eye out for our next update, it could be coming directly to you within the next 60 minutes or so.

Sincerely,

Joel Locke
Senior Editor
The Daily Edge Report

_{DailyEdgeReport.com}_{(“DailyEdgeReport” or “DER” ) is owned by GG Media Holdings LLC, a multi member limited liability company. Data is provided from third-party sources and DER is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile DER brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.}

_{ENvue Medical, Inc. (FEED:US) previously changed their company name and symbols from NanoVibronix Inc. (NAOV:US)}

_{Pursuant to an agreement between GG Media Holdings LLC and TD Media LLC, GG Media Holdings LLC has been hired for a period beginning on 06/02/2026 and ending on 06/03/2026 to publicly disseminate information about (FEED:US) via digital communications. Under this agreement, TD Media LLC has paid GG Media Holdings LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, GG Media Holdings LLC has been paid fifteen thousand USD (“Funds”). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

_{Neither GG Media Holdings LLC, TD Media LLC and their member own shares of (FEED:US).}

_{Please see important disclosure information here:}_{https://dailyedgereport.com/disclosure/feed-0CY5e/#details}